Testing effectiveness (Phase 2)Study completedNCT02839720
What this trial is testing
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Who this might be right for
Cutaneous NeurofibromaNeurofibromatosis Type 1Optic Nerve Glioma
National Cancer Institute (NCI) 11